Podcast Episodes

Episode 38: The Uromigos Virtual World Tour - starting in Vancouver with Atezolizumab in NMIBC

Season 1 Episode 38

Peter Black talks about his recent BCG refractory NMIBC ASCO presentation and its implications for the field. 

6 years, 4 months ago

View Episode

Episode 37: Regoratinib (FGFR inhibitor) and Atezolizumab in UC with Jonathan Rosenberg

Season 1 Episode 37

Everything you wanted to know about FGFR inhibition but were afraid to ask. 

6 years, 4 months ago

View Episode

Episode 36: Dr. Tian Zhang discusses three ASCO bladder cancer abstracts with immune therapy/targeted therapy combinations

Season 1 Episode 36

 Tian Zhang discusses three ASCO bladder cancer abstracts with immune therapy/targeted therapy combinations

6 years, 4 months ago

View Episode

Episode 35: Maintenance Avelumab in Bladder Cancer (LBA1)

Season 1 Episode 35

Dr. Kala Sridhar, Professor Tom Powles and Dr. Brian Rini discuss the data presented at ASCO.

6 years, 4 months ago

View Episode

Episode 34: Savolitinib in Renal Papillary Cancer - A Major Breakthrough?

Season 1 Episode 34

Dr. Toni Choueiri discusses the results of this study, which appears to show a survival signal, but it is difficult to interpret. 

6 years, 4 months ago

View Episode

Episode 33: Adjuvant Atezolizumab in Urothelial Cancer

Season 1 Episode 33

Joaquim Bellmunt explains a bit about why this trial was not successful and what it means for the field. 

6 years, 4 months ago

View Episode

Episode 32: A Phase 2 Study of PSMA PET in Prostate Cancer with Thomas Hope from ASCO 2020

Season 1 Episode 32

Thomas Hope is quizzed on the results of his study presented at ASCO20.

6 years, 4 months ago

View Episode

Episode 31: A Phase 2 Study of Nivolumab with the Addition of Ipilimumab Upon Progression in Renal Cancer

Season 1 Episode 31

Mike Atkins describes the results of this study which helps shed light on the role of ipilimumab and nivolumab in this disease. 

6 years, 4 months ago

View Episode

Episode 30: Update on Axitinib plus Pembrolizumab in Renal Cancer (KEYNOTE 426)

Season 1 Episode 30

Betsy Plimack discusses the updated data with a minimum of 23 months' follow up. Dr. Brian Rini and Professor Tom Powles asks what it adds. 

6 years, 4 months ago

View Episode

Episode 29: PSMA PET at ASCO 2020 with Mike Morris

Season 1 Episode 29

Mike Morris presents the findings in his prospective study. 

6 years, 4 months ago

View Episode